Oncocyte is the biggest potential threat identified so far
Quote:
Originally Posted by
skid
My thoughts also Skid!
The Sienna product is much less of a direct competitor than the Oncocyte product.
Oncocyte's product uses the same PCR based biomarker technology as CxBladder, although presumably they are using a different combination of biomarkers. It appears that they are initially targeting use in indeterminate cytology during recurrence surveillance by Pathologists, ie, cells examined from urine samples that are not able to be identified as cancerous or non-cancerous during the monitoring testing that is performed on patients who have already had bladder cancer treated. This actually makes them a direct competitor with the Sienna product.
Initially the Oncocyte product noted above will not be a direct competitor to CxBladder, but according to slides 23 and 24 of this Oncocyte presentation (Sept 2014), they plan to later introduce a product that deals with routine monitoring, ie, a product that could compete directly with CxBladder Monitor (not yet released), and finally a product that would deal with the initial diagnosis of bladder cancer, ie, a product that could compete directly with CxBladder Detect.
I would estimate (though I am no expert) that they are at least a year away from having their first product in use by Pathologists and probably 2-3 years away from having their later products (the ones that would compete with CxBladder Monitor and Detect) ready for sales. They do not appear to be as far advanced in their product pipeline as PEB, so I am still comfortable backing PEB as a small shareholder.
Disclaimer: Do your own research. I am not a financial advisor and the above information represents my personal opinions on the research that I have undertaken. I am a holder of a small parcel of PEB shares and currently bullish on PEB's future prospects.